tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Meningitis, Fungal D016921 1 associated lipids
Liver Failure D017093 5 associated lipids
IgA Deficiency D017098 2 associated lipids
IgG Deficiency D017099 1 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Polymyositis D017285 1 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Dumont FJ et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. 1990 J. Immunol. pmid:1688572
Woo J et al. Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. 1990 Clin. Exp. Immunol. pmid:1689226
Dumont FJ et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. 1990 J. Immunol. pmid:1689353
Brown Z and Neild GH FK-506 and haemolytic uraemic syndrome. 1990 Lancet pmid:1689442
Thomas J et al. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. 1990 Transplantation pmid:1689518
Murase N et al. Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. 1990 Transplant. Proc. pmid:1689906
Hoffman AL et al. The effect of FK 506 on small intestine allotransplantation in the rat. 1990 Transplant. Proc. pmid:1689907
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Nalesnik MA et al. The effect of FK 506 and CyA on the Lewis rat renal ischemia model. 1990 Transplant. Proc. pmid:1689911
Francavilla A et al. FK 506 as a growth control factor. 1990 Transplant. Proc. pmid:1689912
Mazzaferro V et al. Studies of the hepatotrophic qualities of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689913
Standaert RF et al. Molecular cloning and overexpression of the human FK506-binding protein FKBP. 1990 Nature pmid:1696686
Tropschug M et al. Isolation and sequence of an FK506-binding protein from N. crassa which catalyses protein folding. 1990 Nature pmid:1696687
Randall T New antirejection drugs anticipated. 1990 JAMA pmid:1696999
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Woo J et al. Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. 1990 Transplant. Proc. pmid:1697113
Propper DJ et al. Low-dose FK 506 inhibits sensitisation after blood transfusions. 1990 Transplant. Proc. pmid:1697114
Tiebosch A et al. Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. 1990 Transplant. Proc. pmid:1697115
Murase N et al. Effect of FK 506 on spontaneous diabetes in BB rats. 1990 Diabetes pmid:1700959
Kawashima H and Mochizuki M Effects of a new immunosuppressive agent, FK 506, on the efferent limb of the immune responses. 1990 Exp. Eye Res. pmid:1701148
Siekierka JJ et al. The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. 1990 J. Biol. Chem. pmid:1701173
Johansson A and Möller E Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. 1990 Transplantation pmid:1701570
Reyes J et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. 1990 Transplantation pmid:1701571
Tsuji RF et al. Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system. 1990 J. Antibiot. pmid:1701765
Granelli-Piperno A et al. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. 1990 J. Exp. Med. pmid:1701825
Lee KK et al. Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. 1990 Transplant. Proc. pmid:1702239
Wasik M et al. Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. 1990 Jul-Aug Immunopharmacology pmid:1699911
MacLeod AM and Thomson AW [FK-506. A new immunosuppressive drug]. 1990 Jul-Sep Medicina (Firenze) pmid:1706817
Naouri A and Tissot E [Indications for liver transplantation in adults]. 1990 Jun-Jul J Chir (Paris) pmid:1698800
Gailliot FP et al. Fluidized bed adsorption for whole broth extraction. 1990 Sep-Oct Biotechnol. Prog. pmid:1366874
Jorgensen WL Rusting of the lock and key model for protein-ligand binding. 1991 Science pmid:1719636
Kobayashi N et al. Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. 1991 Transplant. Proc. pmid:1703707
Keenan RJ et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. 1991 Transplantation pmid:1719668
Strasser S et al. The effect of FK 506 on canine pancreatic islet cell function in beagle dogs. 1991 Transplant. Proc. pmid:1703709
Cryan J et al. FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity. 1991 Biochem. Biophys. Res. Commun. pmid:1719972
Ryu S and Yasunami Y Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. 1991 Transplant. Proc. pmid:1703710
Karlsson H et al. The immunosuppressive agent FK506 inhibits in vitro expression of membrane-bound and soluble interleukin-2 receptors on resting but not on activated human lymphocytes. 1991 Immunol. Lett. pmid:1720417
Alejandro R et al. Combined liver-islet allotransplantation in man under FK 506. 1991 Transplant. Proc. pmid:1703712
FK-506 shows similar graft survival rate to cyclosporine but fewer side effects: Pitt transplant team. 1991 Nephrol News Issues pmid:1720511
Ito T et al. The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. 1991 Transplant. Proc. pmid:1703716
Sumpio BE and Phan S Nephrotoxic potential of FK 506. 1991 Transplant. Proc. pmid:1721278
Pichard L et al. Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA. 1991 Transplant. Proc. pmid:1721279
Christians U et al. Interactions of FK 506 and cyclosporine metabolism. 1991 Transplant. Proc. pmid:1721280
Wu YM et al. Interaction between FK 506 and cyclosporine in dogs. 1991 Transplant. Proc. pmid:1721281
Habucky K et al. The pharmacodynamics of pentobarbital following FK 506 therapy. 1991 Transplant. Proc. pmid:1721282
Farghali H et al. Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. 1991 Transplant. Proc. pmid:1721283
Su MS and Semerjian A Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. 1991 Transplant. Proc. pmid:1721310
Andersson J et al. The effects of FK 506 on cytokine production are dependent on the mode of cell activation. 1991 Transplant. Proc. pmid:1721311
Wang SC et al. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. 1991 Transplant. Proc. pmid:1721312
Woo J et al. Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. 1991 Transplant. Proc. pmid:1721313
McCarthy SA et al. Effects of FK 506 and cyclosporine on T-cell tolerance: inhibition of a "protective" mechanism that regulates activation-induced apoptosis in developing thymocytes. 1991 Transplant. Proc. pmid:1721314
Uemoto S et al. Experience with FK 506 in living related donor liver transplantation. 1991 Transplant. Proc. pmid:1721342
Tzakis AG et al. FK 506 versus cyclosporine in pediatric liver transplantation. 1991 Transplant. Proc. pmid:1721343
Mieles LA et al. Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. 1991 Transplant. Proc. pmid:1721344
Nakazato P et al. Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. 1991 Transplant. Proc. pmid:1721345
Nakamura K et al. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. 1991 Transplant. Proc. pmid:1721346
Jain AB et al. Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. 1991 Transplant. Proc. pmid:1721347
de Paulis A et al. Characterization of the anti-inflammatory effect of FK-506 on human mast cells. 1991 J. Immunol. pmid:1721644
Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721374
Christians U et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. 1991 Transplant. Proc. pmid:1703358
Morris SM et al. Disruption of renal function and gene expression by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721375
Lagodziński Z et al. Effect of FK 506 on B-cell responses. 1991 Transplant. Proc. pmid:1703359
Lieberman KV et al. FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). 1991 Transplant. Proc. pmid:1721376
Demetris AJ et al. Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703360
Ueda D et al. Influence of FK 506 on renal blood flow. 1991 Transplant. Proc. pmid:1721377
Thomson AW et al. The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. 1991 Transplant. Proc. pmid:1703361
Perico N et al. FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. 1991 Transplant. Proc. pmid:1721378
Mieles L et al. Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. 1991 Transplant. Proc. pmid:1703362
Warty V et al. Distribution of FK 506 in plasma lipoproteins in transplant patients. 1991 Transplant. Proc. pmid:1703363
Adams CK and Famili P A study of the effects of the drug FK 506 on gingival tissues. 1991 Transplant. Proc. pmid:1721405
Pirsch JD et al. Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient. 1991 Transplant. Proc. pmid:1721406
Shinozuka H et al. Effect of FK 506 on experimental liver carcinogenesis. 1991 Transplant. Proc. pmid:1721407
Pelekanou V et al. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. 1991 Transplant. Proc. pmid:1721408
Tai J et al. In vivo and in vitro effect of FK 506 on rat Leydig cell function. 1991 Transplant. Proc. pmid:1721409
Ito T et al. Bone marrow cell- and FK 506-induced donor-specific unresponsiveness in rat heart allografts. 1991 Transplant. Proc. pmid:1721437
DeValeria PA et al. FK 506 fails to reverse moderate cardiac allograft rejection in a canine heterotopic model. 1991 Transplant. Proc. pmid:1721438
Jiang H et al. Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. 1991 Transplant. Proc. pmid:1721439
Sato K et al. Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. 1991 Transplant. Proc. pmid:1721440
Hohlfeld R [Current therapy of multiple sclerosis: value of cyclosporin A and FK 506]. 1991 Nervenarzt pmid:1709725
Katayama Y et al. Immunosuppressive effects of FK 506 in rat lung transplantation. 1991 Transplant. Proc. pmid:1721441
Kay JE et al. Inhibition of T and B lymphocyte proliferation by rapamycin. 1991 Immunology pmid:1709916
Yokomise H et al. Immunosuppressive effects of FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721442
Ringe D Immunosuppression. Binding by design. 1991 Nature pmid:1710317
Tropschug M and Hofmann R FK506 and protein kinase C. 1991 Nature pmid:1710319
Albers MW et al. Relationship of FKBP to PKCI-2. 1991 Nature pmid:1710782
Stevens C et al. The effects of immunosuppressive agents on in vitro production of human immunoglobulins. 1991 Transplantation pmid:1710843
Nicoletti F et al. FK-506 prevents diabetes in diabetes-prone BB/Wor rats. 1991 Int. J. Immunopharmacol. pmid:1722192
Starzl TE et al. [Clinical experience with FK 506]. 1991 Presse Med pmid:1722311
Granelli-Piperno A and McHugh P Characterization of a protein that regulates the DNA-binding activity of NF-AT, the nuclear factor of activated T cells. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1722332
Simmons RL and Wang SC New horizons in immunosuppression. 1991 Transplant. Proc. pmid:1714645
Nelson PA et al. cDNA encoding murine FK506-binding protein (FKBP): nucleotide and deduced amino acid sequence. 1991 Gene pmid:1722474
Calne RY Immunosuppression for organ grafting. 1991 Transplant. Proc. pmid:1714646
Chen MF et al. The influence of FK-506 on the thymus and spleen in normal C3H/He mice: flow cytometric analysis of lymphocyte subpopulations. 1991 Immunol. Lett. pmid:1722778
Starzl TE et al. Notes on FK 506. 1991 Transplant. Proc. pmid:1714647
Haba T et al. Pathological and immunohistochemical examination in the rat treated with FK 506. 1991 Transplant. Proc. pmid:1714649
Lautenschlager I et al. Efficiency of FK 506 and CyA to prevent acute cellular rejection of pig liver allografts. 1991 Transplant. Proc. pmid:1714650